Published On: Jul 13, 2020

Biotechnology major Biocon says it will launch biologic drug Itolizumab for the treatment of moderate to severe coronavirus patients at a price of around 8,000 per vial. The company has received approval from the Drugs Controller General of India (DCGI) to market Itolizumab injection 25mg/5mL solution for emergency use in India for the treatment of cytokine release syndrome in moderate to severe acute respiratory distress syndrome (ARDS) due to COVID-19. Biocon says Itolizumab is the first novel biologic therapy to be approved anywhere in the world for treating patients with such complications. ET's Divya Rajagopal brings you all the details. (Text: PTI)  

Related Videos

Entertainment Articles